Brookstone Capital Management Acquires 1,876 Shares of Pfizer Inc. (NYSE:PFE)

Brookstone Capital Management grew its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,930 shares of the biopharmaceutical company’s stock after acquiring an additional 1,876 shares during the quarter. Brookstone Capital Management’s holdings in Pfizer were worth $3,587,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Brevan Howard Capital Management LP boosted its position in shares of Pfizer by 61.6% during the fourth quarter. Brevan Howard Capital Management LP now owns 43,091 shares of the biopharmaceutical company’s stock worth $1,241,000 after buying an additional 16,422 shares during the period. Bell Investment Advisors Inc boosted its position in shares of Pfizer by 9.1% during the fourth quarter. Bell Investment Advisors Inc now owns 5,958 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 497 shares during the period. Bayesian Capital Management LP boosted its position in shares of Pfizer by 57.0% during the fourth quarter. Bayesian Capital Management LP now owns 175,200 shares of the biopharmaceutical company’s stock worth $5,044,000 after buying an additional 63,600 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of Pfizer by 26.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 466,252 shares of the biopharmaceutical company’s stock worth $13,423,000 after buying an additional 96,185 shares during the period. Finally, Guardian Wealth Management Inc. boosted its position in shares of Pfizer by 245.7% during the fourth quarter. Guardian Wealth Management Inc. now owns 2,247 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 1,597 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on PFE. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Down 2.8 %

Shares of PFE stock opened at $29.34 on Friday. The stock’s fifty day moving average price is $29.09 and its two-hundred day moving average price is $28.36. The company has a market cap of $166.26 billion, a PE ratio of -489.00, a P/E/G ratio of 1.23 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the business posted $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.73%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.